
Published by Biohacking Elite · Updated November 16, 2026. No independent specialist review is claimed.
What the HHS 503A notice is: On October 30, 2026, HHS published a Federal Register notice (FR Doc. 2026-22192) of a draft, interim enforcement-discretion policy for 503A compounding that uses certain peptide bulk drug substances — Appendix A lists BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 — by state-licensed pharmacies, federal facilities, and licensed physicians.
What it is not: It is not an FDA approval and not a completed 503A bulks-list rule. The notice states that compounded drugs are not FDA-approved and that the draft policy does not establish any rights for any person and is not binding on HHS or the public.
The policy does not apply to research-use-only materials, does not legalize research-use sales, and does not apply to Biohacking Elite’s research-use-only catalog. This page is a document summary, not legal or compounding advice.
On October 30, 2026, HHS published a Federal Register notice of a draft enforcement-discretion policy for 503A compounding that uses certain peptide bulk drug substances. The notice is not an FDA approval. The policy applies to compounding by state-licensed pharmacies, federal facilities, and licensed physicians. It does not apply to research-use-only materials, it does not legalize research-use sales, and it does not apply to Biohacking Elite’s research-use-only catalog.
What this action is
The official notice is FR Doc. 2026-22192, published in the Federal Register, Volume 91, Number 209 (Friday, October 30, 2026), pages 68526–68527. HHS calls it a notice of availability of a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” The policy is interim, while the 503A bulks list is developed through rulemaking.
Both the notice and the policy state that compounded drugs are not FDA-approved, meaning FDA does not review their safety, effectiveness, or quality before they are marketed. In the circumstances set out in the policy, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance listed in Appendix A. HHS may revisit the policy if a safety signal or product quality issue arises. The Federal Register notice also states that the draft policy does not establish any rights for any person and is not binding on HHS or the public.
Appendix A of the official policy lists six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The circumstances the policy lists include the identity and route-of-administration limits in Appendix B; a valid certificate of analysis from a facility registered under section 510 of the Federal Food, Drug, and Cosmetic Act; a single active ingredient from Appendix A; section 503A’s patient-specific prescription requirement; labeling that includes “This is a compounded drug product. Not for resale.”; and reporting of products, serious adverse events, and product quality issues to FDA’s MedWatch program and to the relevant states. This summary is a description of those official conditions, not compounding advice. The notice invited written comments for two weeks after the October 30, 2026 publication date, through Docket No. HHS-OASH-2026-0496.
What USP said on November 3, 2026
On November 3, 2026, the U.S. Pharmacopeia (USP) issued a public statement titled “USP statement on quality and safety considerations for unapproved peptides.” USP said the peptide bulk drug substances addressed by the HHS enforcement discretion policy do not have USP–NF monographs, USP Reference Standards, or established bulk drug substance names (for example, United States Adopted Names, International Nonproprietary Name, or International Union of Pure and Applied Chemistry names) that define their identity and substance-specific quality attributes.
USP also said a scientific review it conducted before the July 2026 Pharmacy Compounding Advisory Committee meeting found that the peptide substances included under the HHS policy are not sufficiently characterized to support consistent evaluation of their quality. In the same statement, USP said the USP standards referenced in the policy cannot, on their own, provide adequate quality assurance for these peptide substances, because they do not establish the substance- and product-specific quality specifications that would come from linking each peptide bulk drug substance to a drug monograph and related reference standard. USP added that neither existing nor potential new USP standards replace a regulator’s role in determining whether a product is safe and effective.
USP’s statement refers to “the peptide bulk drug substances addressed by the HHS enforcement discretion policy.” It does not itself name those substances. The six substances listed in Appendix A of the official HHS policy are the ones named above. USP’s statement is a standards comment. It is not an FDA approval decision, and it does not change the fact that the HHS policy does not apply to research-use-only materials.
Update, November 16, 2026: FSMB FAQ on the HHS policy
On November 10, 2026, the Federation of State Medical Boards (FSMB) issued a five-page FAQ titled “FAQs: Department of Health and Human Services (HHS) Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” The PDF is dated November 10, 2026, carries FSMB’s Washington, D.C. letterhead (www.fsmb.org), and is addressed to state medical boards. A publicly posted copy is available from the Alabama Board of Medical Examiners: FSMB FAQ, November 10, 2026 (PDF).
The FAQ’s central clarifications, as written by FSMB, are:
- The HHS policy describes conditional federal non-enforcement. It is not FDA approval, it does not add the six peptides to the 503A bulks list, and the resulting compounded products remain unapproved compounded drugs.
- The policy does not itself amend state medical or pharmacy practice acts, or direct state boards to suspend their own enforcement.
- Federal non-enforcement does not establish medical necessity or a standard of care.
- The policy has no single fixed expiration date. For each peptide it applies until a final rule decides whether that substance is included on the 503A bulks list, and HHS may revisit the policy, including if a safety signal or product-quality issue arises.
This FAQ does not change the scope of the October 30, 2026 HHS notice for research-use-only materials. It explains the HHS compounding-discretion policy for state medical boards. It is not a rule for research-use catalogs, not legal or medical advice, and not a finding about any research-material lot. Lot documentation still matters for laboratory research materials; see peptide COA verification and third-party tested peptides.
What this action is not
This is not an FDA approval of the six substances, and it is not a completed 503A bulks-list rule. The notice says FDA’s future rulemakings may propose adding some or all of these peptides to that list. The policy’s title and operative language address 503A compounding by state-licensed pharmacies, federal facilities, and licensed physicians. It does not describe enforcement discretion for 503B outsourcing facilities.
The policy is also not a rule for research-use-only catalogs, and it does not treat a research material as a compounded drug or as something approved for human use. It is not a green light for research-use sales. Biohacking Elite is summarizing the official documents for documentation context only. This page is not legal advice, and it is not compounding advice.
Sources: the Federal Register notice (FR Doc. 2026-22192); the policy document linked from that notice at HHS (PDF); and the USP statement of November 3, 2026. The docket page is HHS-OASH-2026-0496; that page loaded as a JavaScript application in this review, so a comment count and a time-stamped deadline were not read from it.
Related verification resources
These official notices concern specific regulator findings and policies. They are not tests of Biohacking Elite’s research-use-only catalog. For a buyer-facing workflow that checks a certificate with the issuing laboratory, and for how to read test-scope claims, start here:
- Peptide COA verification: check the report with the lab
- Third-party tested peptides — test-scope evidence table
- How to verify a peptide COA: Janoshik, Vanguard and MZ Biolabs
For additional research context, see the research library.
About this resource
Biohacking Elite — company editorial resource for laboratory research and documentation literacy. This page summarizes official regulator documents for context. It is not legal advice, medical advice, or a laboratory report, and it is not an endorsement of any compounded, approved, or unapproved drug product.
Research-use only. No medical advice, dosing, administration instructions or human-use recommendations are provided. Nothing here establishes that a research material is suitable for human or animal consumption, or that it is a compounded or approved drug.

